PALLIATIVE
TREATMENT
FOR CACS

CANCER RELATED ANOREXIA-CACHEXIA SYNDROME (CACS)

  • CACS affects ~80% of cancer patients in the advanced stages
  • Progressive weight loss & loss of appetite
  • Skeletal muscle wasting & reduced adipose tissue
  • Involuntary loss of more than 10% of the original weight
  • CACS adversely affects a patient’s quality of life, and negatively predicts treatment outcome

CANNABICS™ SR FOR TREATMENT OF CACS

  • Drug candidate for palliative treatment of Cancer related Anorexia-Cachexia Syndrome (CACS)
  • Proprietary formulation *patent pending
  • Extended release oral capsule
  • Clinically tested for the treatment of CACS
  • Successful Phase III Pilot Study completed at Rambam Medical Center in Israel
  • Peer-reviewed publication

CLINICAL STUDY CONCLUSIONS

  • A weight increase of ≥10% in 17.6% of patients
  • No significant side effects
  • The results justify a larger study with dosage-controlled cannabis capsules in CACS
  • Click to read full study publication